tenofovir has been researched along with tipranavir in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Gallant, JE | 1 |
| Harris, M; Montaner, JS | 1 |
| Piacenti, FJ | 1 |
| Celesia, BM; Massimino, SD; Mavilla, S; Mughini, MT; Nunnari, G; Onorante, A; Russo, R | 1 |
| Clotet, B; Girard, PM; Negredo, E; Neubacher, D; Youle, M | 1 |
| Guhl, C; Heinz, W; Klinker, H; Langmann, P; Leyh, M; Schirmer, D; Weissbrich, B; Winzer, R | 1 |
| Arastéh, K; Bergmann, F; Chaves, RL; Cooper, DA; Cordery, DV; Neto, JL; Robinson, P; Ruxrungtham, K; Scherer, J; Zajdenverg, R | 1 |
3 review(s) available for tenofovir and tipranavir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Management of HIV-infected patients with multidrug-resistant virus.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Oligopeptides; Organophosphonates; Peptide Fragments; Pyridines; Pyrones; Randomized Controlled Trials as Topic; Sulfonamides; Tenofovir; Treatment Failure; Viral Load | 2004 |
An update and review of antiretroviral therapy.
Topics: Adenine; Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Deoxycytidine; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Drugs, Investigational; Emtricitabine; Enfuvirtide; Furans; HIV Envelope Protein gp41; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Oligopeptides; Organophosphates; Organophosphonates; Patient Compliance; Peptide Fragments; Pyridines; Pyrones; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir | 2006 |
2 trial(s) available for tenofovir and tipranavir
| Article | Year |
|---|---|
Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resiStant patients with tipranavir (RESIST) studies.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Pyridines; Pyrones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load | 2007 |
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Proportional Hazards Models; Pyridines; Pyrones; Ritonavir; Sulfonamides; Tenofovir; Young Adult | 2016 |
6 other study(ies) available for tenofovir and tipranavir
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
New antiretroviral agents.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Deoxycytidine; Dioxolanes; Drugs, Investigational; Emtricitabine; Furans; Guanosine; HIV Fusion Inhibitors; Humans; Imidazoles; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Prodrugs; Protease Inhibitors; Pyridines; Pyrones; Quinazolines; Reverse Transcriptase Inhibitors; Sulfonamides; Sulfur Compounds; Tenofovir | 2001 |
Porphyria cutanea tarda in an HIV-1-infected patient after the initiation of tipranavir/ritonavir: case report.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Middle Aged; Organophosphonates; Porphyria Cutanea Tarda; Pyridines; Pyrones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir | 2007 |
Low trough levels of tipranavir in a combination antiretroviral therapy of tipranavir/ritonavir and tenofovir require therapeutic drug monitoring.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Monitoring; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; Humans; Organophosphonates; Peptide Fragments; Pyridines; Pyrones; Retrospective Studies; Ritonavir; Sulfonamides; Tenofovir | 2008 |